CCL2 is increased by treatment with the chemotherapeutic drug docetaxel and protects prostate cancer cells from docetaxel-induced toxicity (256) but when combined with CCL2 blockade, docetaxel had striking impact on tumor suppression (254, 255). Here, CCL2 is linked to neoplasm.